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Fabrizio Carnevale-Schianca,1 Wendy Leisenring,1,2 Paul J. Martin,1,2 Terry Furlong,1
Gary Schoch,1 Claudio Anasetti,1,2 Frederick R. Appelbaum,1,2 Paul A. Carpenter,1
H. Joachim Deeg,1,2 Hans-Peter Kiem,1,2 Rainer Storb,1,2
George B. McDonald,1,2 Richard A. Nash1,2Because morbidity early after hematopoietic cell transplantation (HCT) results in large part from the devel-
opment of acute graft-versus-host disease (GVHD), we previously proposed that a longitudinal assessment
of morbidity involving the skin, liver, and gastrointestinal (GI) tract might provide a more complete, objective
approach for comparing 2 arms of open-label randomized clinical trials for acute GVHD prevention. In this
study, we determined both morbidity across time and GVHD across time in a retrospective analysis of a da-
tabase from an open-label randomized clinical trial comparing tacrolimus/methotrexate and cyclosporine/
methotrexate after myeloablative conditioning and marrow transplantation from HLA-matched unrelated
donors. The results confirm differences in overall morbidity across time in patients with peak grade II-IV
GVHD compared with those with grade 0-I GVHD, but no significant differences in morbidity associated
with grade II GVHD compared with grade 0-I GVHD. We observed less skin morbidity and a trend toward
less liver morbidity across time in the tacrolimus group (P 5 .04 and .09, respectively), but not for GI mor-
bidity or overall morbidity, despite significantly decreased skin and liver stages and overall grades of GVHD
across time in this group. Thus, our objective assessment of differences in morbidity (regardless of cause) as
a measure of acute GVHD in a randomized clinical trial of acute GVHD prevention has only limited utility.
The difficulty of demonstrating clinical benefits from objective parameters, such as survival and morbidity,
and the subjectivity of grading acute GVHD emphasize the need for blinded assessments in clinical trials
of GVHD prevention.
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Acute graft-versus-host disease (GVHD) is a com-
plication of allogeneic hematopoietic cell transplan-
tation (HCT) that contributes significantly to
transplantation-related mortality [1]. Acute GVHD
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6/j.bbmt.2009.03.009assessing the degree of rash, total serum bilirubin,
and diarrhea volume and then, based on the pattern
and severity of organ involvement, assigning a peak
grade [2-5]. This approach has potential limitations,
however. First, other causes of organ dysfunction be-
sides acute GVHD may confound the assessment,
and thus the assignment of stages and overall grades
of GVHD may then require some element of subjec-
tive interpretation [6-8]. This subjectivity increases
the risk of bias in open-label randomized clinical trials
with acute GVHD endpoints [7,8]. Second, acute
GVHD is a process that may persist or relapse over
time, and thus an assessment approach that grades
only the peak severity of the abnormalities ignores
large amounts of data [7,8]. A longer duration of mor-
bidity related to acute GVHD may be associated with
resistance to treatment and could be highly associated
with patient outcomes [8,9]. The importance of749
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established [10]; however,most, if not all, previous ran-
domized clinical trials of interventions forGVHDpro-
phylaxis have been open-label [11-16]. This situation
may be linked to investigators’ belief that effective con-
trol of acute GVHD will result in the improvement of
more objective endpoints like survival, or to the fact
that the type of study intervention prevents effective
blinding of the patient or the transplantation team
[17]. Because more effective control of acute GVHD
may not necessarily improve survival and blinding is
not always feasible for randomized clinical trials, the
approach to assessing interventions on acute GVHD
endpoints requires reevaluation because of the poten-
tial bias associated with the unblinded grading.
A new, potentially more objective method for
assessing the effects of an intervention on acute
GVHD was proposed by Al-Ghamdi et al. [18] based
on the overall morbidity of the target organs measured
longitudinally across time regardless of cause. In their
approach, the assumption is made that if the study
arms of the randomized clinical trial were balanced
for factors that influence the risk for regimen-related
morbidity, then any differences in skin, liver, or gastro-
intestinal (GI) morbidity between the arms would re-
sult from acute GVHD. Furthermore, if differences
between the arms were not detected, then it would
be unlikely that the treatment affected the risk of
GVHD, provided that the study design had adequate
statistical power to detect any true differences. Al-
Ghamdi et al. [18] concluded that there were signifi-
cant differences in morbidity between patients with
peak grade II–IV and grade 0 acute GVHD. They
found no differences in morbidity between their 2
study arms, but no difference in the incidence of the
peak grades of acute GVHD was noted in the clinical
trial that was retrospectively analyzed [19]. Al-Ghamdi
et al.’s study was limited by its small sample size, the
exclusion of patients with grade I acute GVHD from
the analysis, and the lack of assessments before the on-
set of GVHD or during the first 3 weeks after trans-
plantation in patients who did not develop GVHD.
Finally, the lack of difference in the incidence of acute
GVHD between the study arms did not allow an as-
sessment of the methodology under conditions in
which a treatment effect was detected by conventional
methods. Based on the potential of Al-Ghamdi et al.’s
approach and the limitations of their study, we under-
took another analysis of their methodology to assess its
validity.
In the present study, we assessed the relationships
between morbidity and acute GVHD in subjects who
participated in an open-label prospective randomized
clinical trial of acute GVHD prevention comparing
the efficacy of tacrolimus to cyclosporine (CSP) [13].
One goal of this study was to validate the previous ob-
servation that higher peak organ stages and overallgrades of GVHD correlated with greater morbidity
across time during the first 14 weeks after HCT. A sec-
ondgoalwas todeterminewhetherdifferencesobserved
inpeakoverall gradesofGVHDinaprospective clinical
trial translated into differences in morbidity between
the 2 study arms.PATIENTS AND METHODS
Between March 1995 and September 1996, 180
patients at 10 institutions in the United States were en-
rolled in a randomized, open-label, multicenter ran-
domized clinical trial comparing the combination of
tacrolimus andmethotrexate (MTX) and the combina-
tion of CSP and MTX for the prevention of acute
GVHD after marrow transplantation from matched
unrelated donors. The study design, criteria for HLA
donor matching, transplantation procedure, support-
ive care, patient characteristics, and outcomes of the
study have been published previously [13]. In brief,
donor selection was based on typing for HLA-A and
-B antigens with serologic methods, including all splits
defined by the World Health Organization’s Nomen-
clature Committee at the Tenth Histocompatibility
Workshop in November 1987. Typing of HLA-
DRB1 alleles was by DNA hybridization with se-
quence-specific oligonucleotide probes. All patients
had hematologic malignancies and were at low to in-
termediate risk for relapse after HCT. Preparative reg-
imens were assigned according to the treatment
protocols at the investigational sites. Unmodified do-
nor marrow was infused on day 0.
Tacrolimus was given initially at a dose of 0.03mg/
kg/day and CSP at a dose of 3 mg/kg/day as a continu-
ous i.v. infusion over 24 hours starting on day—1. The
oral formulations were later given at a ratio of 4:1 in 2
divided doses for both drugs. During the first 8 weeks,
tacrolimus and CSP whole blood trough concentra-
tions were maintained at 10 to 30 ng/mL and 150 to
450 ng/mL, respectively. In the absence of GVHD,
doses were tapered beginning at week 9, and adminis-
tration was discontinued at 6 months after transplanta-
tion. The MTX dose was 15 mg/m2 on day 1 and 10
mg/m2 on days 3, 6, and 11 after HCT. All patients re-
ceived either prophylactic or preemptive cytomegalo-
virus therapy and antifungal prophylaxis according to
institutional protocols.
Diagnosis and Treatment of GVHD
During the study period, an overall peak grade of
acute GVHD was assigned by the site investigator at
each institution according to modified Seattle criteria,
and these grades were used to evaluate the primary
endpoint as described previously [2-4,13]. Biopsy
specimens were obtained when indicated to corrobo-
rate the clinical diagnosis of GVHD. In addition, an
Table 1. Longitudinal Assessment of Morbidity and Its Mod-
ifications Based on Inclusion of Upper GI Symptoms and GI
Scoring System
A. Single-System Morbidity
Skin Liver
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to independently assess the acute GVHD endpoint for
each patient. Patients received primary treatment with
corticosteroids and continued receiving tacrolimus or
CSP according to the original randomization.Single-System
Staging
(% of Body
Surface Area)
(Serum Total
Bilirubin Level) GI Score*,†
1 # 25% 2.0 to 2.9 mg/dL 1
2 26% to 50% 3.0 to 5.9 mg/dL 2
3 > 50% 6.0 to 14.9 mg/dL 3-4
4 Bullae $ 15 mg/dL 5-7
B. Overall Morbidity
Grade Skin Stage Liver Stage GI Stage
1 1-2 0 0
2 3 1 1
3 2-3 2-3
4 4 4 4
*The longitudinal assessment of overall morbidity was also performed
including upper GI tract symptoms. For this modification, if nausea
and vomiting were present and were the only symptoms reported,
then a score of 1 was assigned. Otherwise, nausea and vomiting were
not considered for GI stage in the presence of diarrhea, abdominal
pain, or visible blood.
†Scores of 1, 2, and 3 were assigned for diarrhea with average daily vol-
umes < 1000mL, 1000 to 1499 mL, and > 1500mL, respectively. A score
of 2 was assigned when abdominal cramps were present and also when
overt blood was visible in the stool, for a potential total score of 7.Longitudinal Assessment of Morbidity and
Acute GVHD in the Skin, Liver, and GI Tract
During the clinical study, assessments of rash,
serum bilirubin level, nausea, and average daily stool
volume were recorded weekly from marrow infusion
until day 100 after HCT. Additional weekly notations
recorded the presence of overtly visible blood in stool
or abdominal cramping. At each investigational site,
the attribution of organ morbidity to GVHD or an-
other cause also was recorded. Weekly stages and
grades of acute GVHD were assigned to patients by
the site investigators based on clinical parameters
and biopsy results if available [3,4,13]. An overall
peak grade of acute GVHD also was assigned to pa-
tients by the site investigators for the period between
day 0 and day 100.
For the longitudinal assessment of morbidity, stag-
ing of organs and grading for overall morbidity were
modified from the system used for grading acute
GVHD (Table 1) [18]. Morbidity was defined as any
skin rash, GI dysfunction (eg, diarrhea, cramps, bloody
stool), or liver dysfunction resulting in hyperbilirubi-
nemia regardless of cause. Stages for specific organ
morbidity and grades for overall morbidity were as-
signed for each week after HCT regardless of cause.
The causes of morbidity after HCT included, but
were not limited to, regimen-related toxicities, infec-
tions, drug-related adverse effects, and GVHD. For
all organs, a morbidity stage 0 indicated normal func-
tion. Skin morbidity was categorized according to the
extent of rash or erythema and the presence of bullae as
follows: stage 1, # 25% of body surface area; stage 2,
26% to 50% of body surface area; stage 3, . 50% of
body surface area; or stage 4, wet desquamation with
tenderness or bullae formation (or both). Desquama-
tion or bullae formation were considered relevant in
assigning stage 4 skin morbidity only in the presence
of rash or erythema involving . 50% of the skin sur-
face area; otherwise, these manifestations were classi-
fied as skin stage 3. Liver morbidity was categorized
according to the serum total bilirubin concentration
as follows: stage 1, 2.0 to 2.9 mg/dL; stage 2, 3.0 to
5.9 mg/dL; stage 3, 6.0 to 14.9 mg/dL; or stage 4, $
15 mg/dL. GI morbidity was staged according to the
previously published scoring system and included
symptoms of diarrhea, cramps, and overtly visible
blood in stool [18]. Scores of 1, 2, and 3 were assigned,
respectively, for diarrhea with average daily volumes\
1000 mL, 1000 to 1499 mL, and . 1500 mL. A score
of 2 was assigned for the presence of either abdominalcramps or overt blood in the stool for a potential total
score of 7. Overall stages 1, 2, 3, and 4 were assigned,
respectively, for total GI symptom scores of 1, 2, 3 to 4,
and 5 to 7. If urinary mixing was present in the assess-
ment of diarrhea volume, then a score of 1 was assigned
when the average daily volume was\ 1000 mL and it
was the only sign of GI disease. The longitudinal
assessment of GI morbidity was repeated with consid-
eration of anorexia, nausea, and vomiting for deter-
mining the overall score. If nausea and vomiting
were present and were the onlyGI symptoms reported,
then a score of 1 was assigned; otherwise, anorexia,
nausea, and vomiting were not considered in the score
in the presence of diarrhea, abdominal pain, or visible
blood. Grade 1 overall morbidity was defined as stage
1-2 skin morbidity with stage 0 liver andGImorbidity.
Grade 2 overall morbidity was defined as stage 3 skin
morbidity or stage 1 liver or GI morbidity. Grade 3
overall morbidity was defined as stage 2-3 liver or GI
morbidity. Grade 4 overall morbidity was assigned
for patients with stage 4morbidity in the skin, GI tract,
or liver.Statistical Analysis
A longitudinal method was used to assess morbid-
ity to allow for the fact that morbidity changes with
time after transplantation. Curves were fit to morbid-
ity scores (0, 1, 2, 3, or 4) across time. Differences
Figure 1. A, Grade 1-4 overall morbidity for weeks 1 to 14 after HCT
for all study patients. The proportion of patients with grade 1-4 overall
morbidity for each week after HCT is represented by the height of the
bar. The contribution of each grade of morbidity to the total is repre-
sented by different shades of the bar according to the key at the top
of the figure. B, Grade I-IV acute GVHD from weeks 1 to 14 after
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grades of acute GVHD or study arm (patients with
peak grade 0 vs those with peak grade III-IV acute
GVHD, patients with grade 0-I vs those with grade
II acute GVHD, and those with grade III-IV acute
GVHD or, alternatively, tacrolimus vs CSP) were
compared using an odds ratio (OR) for the proportions
of patients with scores above specific thresholds of
morbidity (0, 1, 2, or 3). This analysis assumed an iden-
tical OR for all thresholds; accordingly, the OR for
a score . 3 was the same as the OR for a score . 2.
The analysis also assumed that the general shape of
the curves describing morbidity over time was the
same for the 2 groups being compared. Plots of pre-
dicted values were compared with observed values to
validate these assumptions. Statistical significance
and confidence intervals (CIs) were estimated from
the OR and the corresponding variance estimate. In
more technical terms, ordinal regression methods
were used to evaluate differences between groups in
ordered categorical distributions of morbidity grades
measured at weekly intervals. Cubic spline functions
with 5 knots were included in the model for the time
variable. The proportional odds model was then fit
to the ordered categories, using robust sandwich vari-
ance estimates to account for themultiple observations
contributed across time by each subject [20,21]. An ad-
ditional analysis was performed to assess the impact of
morbidity scores on nonrelapse mortality. Morbidity
scores were used as time-dependent covariates in
a Cox regression model, with nonrelapse death by
day 100 posttransplantation as the outcome of interest
to obtain hazard ratios (HRs) and associated 95% CIs.
Patient follow-up was censored at the relapse date,
date of last contact, or day 100 after HCT, whichever
came first.HCT for all study patients. The proportion of patients with overall grade
I-IV acute GVHD is represented by the height of the bar for each week
after transplantation. The contribution of each grade of GVHD to the
total is represented by different shades of the bar according to the
key at the top of the figure. Comparing A and B shows that the propor-
tion of patients with grade 1-4 overall morbidity is substantially greater
than the proportion of patients with grade I-IVacute GVHD, especially in
the first weeks after HCT but continuing to a lesser degree to week 14.
The numbers at the top of each bar in the graph of both figures repre-
sent the number of subjects available for the analysis at each of the
weekly time points.RESULTS
Overall Morbidity and Acute GVHD in the First
100 Days after HCT
Using the staging and grading system for morbid-
ity after HCT described by Al-Ghamdi et al. [18], we
found a high prevalence of overall morbidity before
week 5, likely related to regimen-related toxicity, fol-
lowed by a progressive decrease in morbidity (Fig-
ure 1A). Whereas the skin and liver exhibited stable
trends toward less morbidity with increased time
from transplantation, the prevalence of stage 1-4 GI
morbidity was initially high and then had a more fluc-
tuating trend, with persistence of significant morbidity
to week 14 after HCT (data not shown). The profile
for the prevalence of acute GVHD was similar, but
the proportions were substantially lower during the
early weeks after HCT (Figure 1B). The differences
between Figures 1A and 1B demonstrate substantialmorbidity attributed to causes other than acute
GVHD persisting to week 14 after HCT.Comparison of Morbidity with Peak Severity of
Acute GVHD (Seattle Criteria)
Higher peak grades of acute GVHD were associ-
ated with a longer duration of GVHD manifestations,
and there was a trend toward a longer duration of mor-
bidity. The median proportion of weeks at grade 2 or
higher morbidity was 0.63 in patients with peak grade
Table 2. Comparison of Morbidity Across Time Based on
Grade of Acute GVHD (Seattle Criteria) in Single-System and
Overall Stages (Ordinal Regression Model)
A. Weeks 1 to 14, Peak Grade III-IV Versus 0-II
Morbidity OR* 95% CI P value
Overall 3.1 1.9 to 4.9 < .01
Skin 5.1 3.7 to 7.2 < .01
GI 5.7 3.0 to 10.9 < .01
Liver 15.9 7.0 to 36.2 < .01
B. Weeks 1 to 14, Peak Grade II-IV Versus 0-I
Morbidity OR* 95% CI P value
Overall 1.4 1.0 to 2.0 .05
Skin 5.6 3.8 to 8.3 < .01
GI 3.6 2.2 to 6.1 < .01
Liver 7.4 3.9 to 14.1 < .01
*An OR >1.0 indicates an increased morbidity in grade III-IV compared
with grade 0-II acute GVHD in part A and an increased morbidity in
grade II-IV compared with grade 0-I acute GVHD in part B.
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those with peak grade II acute GVHD (n 5 71) (P\
.01). The median proportion of weeks at acute
GVHD grade II or higher was 0.36 in patients with
a peak of grade III-IV and 0 in those with a peak of
grade II (P\ .01).
Skin, liver, GI tract, and overall morbidity distri-
butions across time during the first 14 weeks after
HCT were higher in patients with peak grade III–IV
acute GVHD compared with those with peak grade
0-II GVHD (all P\ .01) (Table 2A; Figure 2). Skin,
GI, and liver morbidity distributions also were signif-
icantly higher in patients with peak grade II-IV acute
GVHD than in those with peak grade 0–I acute
GVHD (P \ .01) (Table 2B), but the difference in
overall morbidity between the 2 groups was only mar-
ginally significant (OR5 1.4; P5 .05). Further analy-
ses comparing acute GVHD peak grade 0-I to grades
II and III-IV separately found a significant difference
in morbidity between peak grades 0-I and III-IV
(OR 5 3.0; P\ .01), but no significant difference be-
tween peak grades 0–I and II (OR 5 1.0; P 5 .94). To
decrease the contribution of the morbidity related to
the conditioning regimen, the analysis was repeated
for events fromweeks 3 to 14 only; however, the results
were not changed significantly in any category (data
not shown). The inclusion of nausea and vomiting in
the staging of GI morbidity did not improve the asso-
ciation of overall morbidity with peak grade of acute
GVHD (data not shown).
Association of Morbidity and Acute GVHD with
Day-100 Nonrelapse Mortality
An overall morbidity grade of 3-4 was associated
with a significantly higher hazard of death compared
with a grade of 0 (HR5 20.9; P\ .001), but not com-
pared with an overall grade of 2 (HR 5 0.4; P 5 .36).
The hazard of death was significantly higher with over-
all acute GVHD grade III-IV compared with grade
0 (HR 5 4.6; P\ .001), but not compared with grade
II (HR5 0.9; P5 .86). Higher grades of morbidity and
acute GVHD were associated with increased nonre-
lapse mortality.
Comparison of Morbidity Across Time and
GVHDAcross Time in the 2 Study Arms
The 2 arms of the study population were balanced
with regard to all variables, including the number of
deaths before day 100 (P 5 .49), number of relapses
by day 100 (P5 .19), and number of patients followed
for 14 weeks (P5 .76) (Table 3).Morbidity across time
was not significantly different in the 2 arms for GI,
liver, or overall morbidity (Table 4). Compared with
the CSP group, the tacrolimus group exhibited less
skin morbidity across time and a trend toward less liver
morbidity (OR 5 1.5, P 5 .04 vs OR 5 1.6, P 5 .09).When the analysis was performed for the week 3 to 14
period, these ORs did not change significantly (data
not shown). The analysis performed using GVHD
across time demonstrated significantly less skin, liver,
and overall GVHD (P\ .01, P5 .02, and P\ .01, re-
spectively), but not GI GVHD (P5 .33), in the tacro-
limus group (Table 4). These differences between the
2 arms also were seen in acute GVHD peak stage and
grade for skin, liver, and overall GVHD (P\ .01; P\
.01, and P 5 .02, respectively), but not for GI GVHD
(P 5 .67). We also assessed overall and organ-specific
morbidity in patients with peak grades 0 and I acute
GVHD to determine whether morbidity was differen-
tially attributed between the 2 study arms due to the
open-label design of the clinical trial. No significant
imbalances in morbidity were observed between the
study arms for any of these groups. Thus, an imbalance
in non-GVHD morbidity cannot explain the lack of
significant differences in organ-specific or overall mor-
bidity between the 2 study arms.DISCUSSION
The conventional systems for grading acute
GVHD provide useful measurements of disease sever-
ity for treatment purposes. But these grading systems
can be biased by subjective assessment and represent
a single-event statement thatmight not provide an ideal
method for evaluating results in randomized clinical
trials in which GVHD is an outcome of interest [2,4-
8,22]. To overcome these deficiencies, we have pro-
posed a novel method for assessing the effect of study
interventions on acute GVHD in randomized clinical
trials based on a longitudinal evaluation of morbidity
regardless of cause [18]. This approach could be used
as a study endpoint and would not necessarily replace
Table 3. Event Distribution in the CSP and Tacrolimus
Groups
CSP
(n 5 90)
Tacrolimus
(n 5 90) P value
Number of deaths 45 41 .55
Number of deaths before
day 100
24 20 .49
Number of relapses 14 18 .44
Number of relapses before
day 100
3 7 .19
Number of patients with
data at 13 or 14 weeks
54 52 .76
Days to death in deceased
patients, median (range)
69 (9 to 659) 105 (11 to 514) .62
Days to relapse in relapsed
patients, median (range)
161.5 (75 to 655) 126.5 (53 to 700) .15
Figure 2. Grade 1-4 overall morbidity for weeks 1 to 14 after HCT for
patients with peak grade 0-II acute GVHD (A) and peak grade III-IV acute
GVHD (B). The differences in morbidity between grade 0-II and grade
III-IV acute GVHD are most apparent after week 5. Early morbidity in
both groups resulted from regimen-related toxicity. The numbers at
the top of each bar in the graph represent the number of subjects avail-
able for the analysis at each of the weekly time points.
Table 4. Comparison of Morbidity and GVHD Stage and
Grade across Time from Weeks 1 to 14 in the CSP and
Tacrolimus Groups
Morbidity across Time GVHD across Time
OR* 95% CI P value OR* 95% CI P value
Overall 1.3 0.9 to 1.8 .14 2.3 1.5 to 3.5 < .01
Skin 1.5 1.0 to 2.3 .04 2.3 1.5 to 3.6 < .01
GI 1.0 0.7 to 1.4 .90 1.4 0.7 to 2.9 .33
Liver 1.6 0.9 to 2.6 .09 3.1 1.2 to 7.6 .02
*An OR > 1.0 in the ‘‘morbidity across time’’ column indicates greater
overall or organmorbidity in the CSP arm compared with the tacrolimus
arm. Similarly, an OR > 1.0 in the ‘‘GVHD across time’’ column indicates
greater overall or organ acute GVHD in the CSP arm compared with in
the tacrolimus arm.
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We hypothesize that if the arms of the study were well
balanced with respect to factors influencing morbidity
after HCT, then any difference in morbidity involving
the skin, liver, and GI tract between the treatment
groups should be related to the incidence and severity
of GVHD. In the present study, we found a high prev-
alence of skin, liver, GI, and overall morbidity during
the first 3 to 5 weeks afterHCT,most likely due to reg-
imen-related toxicity. After week 5, morbidity de-
creased more in the patients with grade 0–II acute
GVHD compared with those with grade III-IV acute
GVHD (as defined by the modified Seattle criteria).
But substantial persistence of non–GVHD-related
morbidity remained until week 14, possibly contribut-
ing to the difficulty in grading acute GVHD even after
resolution of regimen-related toxicity.
Our morbidity across time analysis was able to de-
tect differences in overall grade and stage of skin, GI,
and liver morbidity between patients with peak grade
0-II and peak grade III-IV acute GVHD. Importantly,no difference in overall morbidity between grade 0-I
and grade II acute GVHD was found. This finding
may have implications for the sample size required in
clinical trials to detect differences in morbidity regard-
less of cause related to better prevention of acute
GVHD. Compared with a randomized clinical trial
in which the endpoint were peak grade II-IV acute
GVHD, an larger sample size likely would be required
if the expected differences in morbidity between the
study arms were associated primarily with peak grade
III-IV acute GVHD. The lack of difference in overall
morbidity between peak grades 0-I and II acute
GVHD also may explain the markedly decreased inci-
dence of acute GVHD identified by our EPEC com-
pared with the incidence reported by the site
investigators. Most of the cases of acute GVHD iden-
tified by the EPEC had been reported by the site inves-
tigators as grade III-IV, even though most cases of
acute GVHD relevant to the study endpoint were
grade II [13,17]. Morbidity across time measurements
in randomized clinical trials are likely to detect primar-
ily the differences between study arms associated with
severe acute GVHD.
Grade 3-4 morbidity and grade III-IV acute
GVHD were associated with an increased risk of non-
relapse mortality, whereas grade 2 morbidity and
grade II acute GVHD were not. Previous studies
Biol Blood Marrow Transplant 15:749-756, 2009 755Morbidity Across Time for Acute GVHD Assessmentalso have failed to demonstrate a strong association be-
tween mortality and overall grade II acute GVHD
[9,23]. Because grade II acute GVHD was not associ-
ated with increased morbidity or increased risk of non-
relapse mortality, the incidence of grade III-IV acute
GVHD can be considered the most relevant endpoint
for clinical trials of GVHD prevention. This endpoint
has some limitations, however, because the difference
between grade II and grade III-IV acute GVHD re-
flects both the efficacy of the prophylaxis regimen
and the efficacy of any treatment for acute GVHD.
In addition, the distinction between grade II and
higher grades of acute GVHD cannot be made reliably
and consistently in patients who have other GI or he-
patic complications.
The EPEC, which was blinded to study arm and
GVHD treatment, found a lower incidence of
GVHD in the tacrolimus group compared with the
CSP group. Although the overall incidence of acute
GVHD found in the EPEC analysis was substantially
lower than that reported by the study investigators, it
confirms the treatment effect observed by the un-
blinded assessment of acuteGVHDby study investiga-
tors [10,17]. The longitudinal analysis of morbidity did
find significantly less skin morbidity in the tacrolimus
group, but no difference in the overall grades of mor-
bidity between the 2 study arms. The lower skin mor-
bidity and the trend toward lower liver morbidity in
the tacrolimus group are consistent with the EPEC’s
findings [13]. The failure to observe a greater effect
on morbidity with a significant reduction in the inci-
dence of conventionally graded acute GVHD may be
associated with the large number of morbidity events
related to causes other than GVHD. The increased
use of corticosteroids for the primary treatment of
GVHD in the CSP group also may have mitigated
the potential difference in morbidity compared with
the tacrolimus group [13]. Although an analysis ofmor-
bidity across time is potentiallymore objective, because
it does not require the assignment of cause, here it
appears to increase the likelihood of not detecting an
effective therapy for GVHD prevention as determined
by the EPEC. Compared with the CSP group, the
tacrolimus group had significantly lower rates of skin,
liver, and overall acute GVHD but a similar rate of
GI acute GVHD across time. Why tacrolimus’s major
effect was a reduction of skin and liver acute GVHD is
not clear. The HRs obtained by comparing tacrolimus
and CSP were similar for peak acute GVHD grade and
GVHD across time. In this study, the longitudinal
analysis of morbidity and acute GVHD did not appear
to be more informative than the analysis of peak grade
of acute GVHD for assessing the differences between
study arms.
In summary, here we report a novel approach to as-
sessing morbidity across time after allogeneic HCT
and describe how it might be used as a surrogate end-point for acute GVHD. Our findings demonstrate the
feasibility of a longitudinal assessment of morbidity in
skin, liver, and GI tract in a randomized clinical trial.
However, contrary to our original assumption, consid-
erable morbidity not related to acute GVHD was ob-
served even after the expected resolution of regimen-
related toxicity. Significant differences between the 2
arms of the randomized clinical trial were found for
acute GVHD across time and for peak stages and
grades of acute GVHD, but not for overall morbidity.
The lack of difference in overall morbidity between
grade 0-I and grade II acute GVHD and the presence
of considerable morbidity unrelated to GVHD limits
the utility of this method in a randomized clinical trial
of GVHD prevention and likely would require a larger
patient sample size for detecting significant differences
in severe acute GVHD between the study arms. In ad-
dition, factors that might affect the morbidity of acute
GVHD and are not balanced between the 2 arms (most
notably the duration and intensity of other immuno-
suppressive treatment after diagnosis of GVHD)
would need to be considered in the interpretation of
the outcomes of GVHD studies. Although the evalua-
tion of morbidity and GVHD across time may be in-
formative, it might best serve as a descriptive analysis
or a secondary endpoint rather than a primary end-
point of a randomized clinical trial of GVHD preven-
tion. In open-label studies, a carefully constructed
EPEC analysis with blinding of investigators to both
investigational intervention and GVHD treatment ap-
pears to be the best option for minimizing bias in eval-
uating acute GVHD endpoints.ACKNOWLEDGMENTS
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